Fate expands solid-tumor collaboration with Ono to include CAR NK cells, second target

FATE THERAPEUTICS INC

Ono contributes novel binding domains for a second solid tumor antigen; partnership now includes CAR NK and CAR T-cell candidates.
Fate receives research funding through Sep 2024 and is eligible for an option exercise fee, milestones, and tiered royalties.
Fate retains global manufacturing rights and the right to co-develop and co-commercialize in the US and Europe.
First iPSC-derived CAR T-cell product candidate targeting solid tumors is advancing toward clinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.